Eupraxia Pharmaceuticals Inc.
NASDAQ:EPRXBiotechnology
+$0.07 today
- Market cap
- $417.57M
- Beta
- 1.48
- P/E (TTM)
- -8.5
- EPS (TTM)
- -$0.74
Volume 1.21M
Average 0.22M
EPRX EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Eupraxia Pharmaceuticals Inc.NASDAQ: EPRX
EBITDA · Q1 FY2026 · quarter ended Mar 2026
EBITDA remains negative
Q1 FY2026 EBITDA was -$15.65M, compared with -$6.72M a year earlier. Trailing-twelve-month EBITDA was -$45.49M.
Context
- EBITDA grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether EBITDA reaches the consensus estimate of $0 (+100.0%) for the fiscal year ending Dec 2026, a step up from the -113.7% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$15.65M+6.0% QoQ
- Last fiscal yearDec 2025
- -$53.33M-113.7% YoY
- LTMMar 2026
- -$45.49M-75.7% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -132.9% | +100.0% | +232.9 pp |
| 1 year | -113.7% | +100.0% | +213.7 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
Mixed currencies · from the income statement
- Latest · FY2025
- (53.33M) USD
- Year-over-year change
- -113.7%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (53.33M) | -113.7% |
| FY2024 | 2024-12-31 | (24.95M) | -20.0% |
| FY2023 | 2023-12-31 | (20.78M) | — |
| FY2022 | 2022-12-31 | (17.86M) | -3.7% |
| FY2021 | 2021-12-31 | (17.22M) | — |
EBITDA vs competitors
How EPRX compares with its peers on the latest reported figures
- Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -75.7% is the 6th highest of 9, against a peer median of -14.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | -$14.84M USD | +39.0% | — | 102.5% | |
| LTM Mar 2026 | -$35.22M USD | — | — | — | |
| LTM Sep 2026 | -$35.76M USD | -89.6% | — | — | |
EPRXEupraxia Pharmaceuticals Inc. | LTM Mar 2026 | -$45.49M USD | -75.7% | — | — |
| LTM Mar 2026 | -$50.77M USD | +11.7% | — | — | |
| LTM Mar 2026 | -$52.72M USD | +20.1% | — | 161.1% | |
| LTM Mar 2026 | -$62.94M USD | -39.6% | — | — | |
| LTM Mar 2026 | -$69.83M USD | -147.0% | — | — | |
| FY2025 | -€128.15M EUR | +23.0% | — | 2858.6% | |
| LTM Mar 2026 | -$158.55M USD | -341.7% | — | 8932.3% | |
| Peer median (excluding EPRX) | — | -14.0% | — | 1509.8% | |
Competitors are the stored peer set for EPRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 · CAD | FY2022 Dec 2022 · CAD | FY2023 Dec 2023 · USD | FY2024 Dec 2024 · USD | FY2025 Dec 2025 · USD |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 112.38K | 0 | 0 | 163.47K | 331.89K |
| Gross Profit | (112.38K) | 0 | 0 | (163.47K) | (331.89K) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 7.59M | 13.63M | 15.33M | 16.07M | 29.51M |
| Selling, General & Admin | 6.97M | 3.99M | 5.63M | 10.92M | 17.1M |
| Operating Expenses | 14.65M | 17.62M | 20.97M | 26.99M | 53.33M |
| Depreciation & Amortization | 87.47K | 147.89K | 117.1K | 171.6K | 331.89K |
| EBITDA | (17.22M) | (17.86M) | (20.78M) | (24.95M) | (53.33M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (14.65M) | (17.62M) | (20.97M) | (26.99M) | (53.66M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 51.55K | 431.8K | 649.75K | 1.16M | 1.41M |
| Interest Expense | 1.02M | 982.86K | 881.05K | 603.17K | 0 |
| Other Income / Expenses | (3.68M) | (1.37M) | (814.93K) | 1.26M | (212.94K) |
| Income Before Tax | (18.33M) | (18.99M) | (21.78M) | (25.73M) | (53.87M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 27.42K | 1.8K | 26.65K |
| Net Income | (18.03M) | (18.49M) | (21.25M) | (25.49M) | (53.86M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (1.63) | (0.96) | (0.88) | (0.76) | (1.05) |
| EPS (Diluted) | (1.63) | (0.96) | (0.88) | (0.76) | (1.05) |
| Weighted Avg Shares | 14.24M | 19.29M | 24.15M | 33.93M | 39.96M |
| Weighted Avg Shares (Diluted) | 14.24M | 19.29M | 24.15M | 33.93M | 39.96M |
Eupraxia Pharmaceuticals Inc.
NASDAQ:EPRX
Intrinsic Alpha fair value
Locked
Current Price
$6.21
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.